{"id":20109,"date":"2025-10-25T17:12:26","date_gmt":"2025-10-25T10:12:26","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=20109"},"modified":"2025-10-25T17:58:17","modified_gmt":"2025-10-25T10:58:17","slug":"phenindione-tablets","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/phenindione-tablets\/","title":{"rendered":"Phenindione Tablets"},"content":{"rendered":"

Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n

Action and use<\/strong><\/p>\n

Oral anticoagulant (indanedione).<\/p>\n

DEFINITION<\/h2>\n
Phenindione Tablets contain Phenindione.<\/p>\n
The tablets comply with the requirements stated under Tablets and with the following requirements.<\/p>\n
Content of phenindione, C_{15<\/sub>H_{10<\/sub>O_{2<\/sub><\/strong><\/p>\n}}}
95.0 to 105.0% of the stated amount.<\/p>\n
IDENTIFICATION<\/h2>\n
Shake a quantity of the powdered tablets containing 0.2 g of Phenindione with 50 mL of dichloromethane, filter and evaporate the filtrate to dryness. The infrared absorption spectrum of the residue, Appendix II A, is concordant with the reference spectrum of phenindione (RS 268).<\/p>\n
TESTS<\/h2>\n
Dissolution<\/h3>\n
Comply with the requirements for Monographs of the British Pharmacopoeia in the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n
TEST CONDITIONS<\/h4>\n
(a)\u00a0 Use Apparatus 1, rotating the basket at 100 revolutions per minute.<\/p>\n
(2) Use 900 mL of a solution containing 0.68% w\/v of potassium dihydrogen phosphate and 0.18% w\/v of sodium hydroxide, pH adjusted to 8.0, at a temperature of 37\u00b0, as the medium.<\/p>\n
PROCEDURE<\/h4>\n
(1) After 45 minutes withdraw a sample of the medium, filter through a 0.45-\u00b5m nylon filter. Measure the absorbance of the filtrate, suitably diluted with the dissolution medium if necessary, at the maximum at 328 nm, Appendix II B using dissolution medium in the reference cell.<\/p>\n
(2) Measure the absorbance of a suitable solution of phenindione BPCRS using dissolution medium in the reference cell, at the maximum at 328 nm.<\/p>\n
DETERMINATION OF CONTENT<\/h4>\n
Calculate the total content of Phenindione, C_{15<\/sub>H_{10<\/sub>O_{2<\/sub>, in the medium from the absorbances obtained and using the declared content of C_{15<\/sub>H_{10<\/sub>O_{2<\/sub> in phenindione BPCRS.<\/p>\n}}}}}}
Related substances<\/h3>\n
Carry out the method for liquid chromatography, Appendix III D, using the following solutions prepared immediately before use.<\/p>\n
(1) Mix with the aid of ultrasound a quantity of the powdered tablets containing 25 mg of Phenindione in methanol. Add sufficient methanol to produce a solution expected to contain 0.25% w\/v of Phenindione, centrifuge and use the supernatant liquid.<\/p>\n
(2) Dilute 1 volume of solution (1) to 100 volumes with methanol.<\/p>\n
(3) 0.00375% w\/v of phenindione impurity 1 BPCRS in methanol.<\/p>\n
(4) 0.0005% w\/v of phenindione BPCRS, phenylacetic acid (impurity 3), benzalphthalide (impurity 4) and phthalic acid (impurity 5) in methanol.<\/p>\n
(5) Dilute 1 volume of solution (2) to 10 volumes with methanol.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
(a) A stainless steel column (10 cm \u00d7 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (3.5 \u00b5m) (X-bridge shield C18 is suitable).<\/p>\n
(b) Use gradient elution and the mobile phase described below.<\/p>\n
(c) Use a flow rate of 1.5 mL per minute.<\/p>\n
(d) Use a column temperature of 30\u00b0.<\/p>\n
(e) Use an autosampler temperature of 4\u00b0.<\/p>\n
(f) Use a detection wavelength of 220 nm.<\/p>\n
(g) Inject 10 \u00b5L of each solution.<\/p>\n
MOBILE PHASE<\/h4>\n
Mobile phase A<\/em><\/p>\n
10 volumes of acetonitrile, 10 volumes of a 1.36% w\/v dipotassium hydrogen phosphate solution previously adjusted to pH<\/p>\n
3.0 with orthophosphoric acid and 80 volumes of water.<\/p>\n
Mobile phase B<\/em><\/p>\n
10 volumes of water and 90 volumes of acetonitrile.<\/p>\n\n\n\n\n\n\n\n\n\n
Time(Minutes)<\/strong><\/td>\n Mobile phase A (%v\/v)<\/strong><\/td>\n Mobile phase B (%v\/v)<\/strong><\/td>\n Comment<\/strong><\/td>\n<\/tr>\n
0-0.5<\/td>\n 80<\/td>\n 20<\/td>\n isocratic<\/td>\n<\/tr>\n
0.5-10<\/td>\n 80\u219250<\/td>\n 20\u219250<\/td>\n linear gradient<\/td>\n<\/tr>\n
10-13<\/td>\n 50<\/td>\n 50<\/td>\n isocratic<\/td>\n<\/tr>\n
13-21<\/td>\n 50\u219230<\/td>\n 50\u219270<\/td>\n linear gradient<\/td>\n<\/tr>\n
21-22<\/td>\n 30\u219280<\/td>\n 70\u219220<\/td>\n linear gradient<\/td>\n<\/tr>\n
22-25<\/td>\n 80<\/td>\n 20<\/td>\n re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to phenindione (retention time, about 7 minutes) are: impurity 5, about 0.2; impurity 3, about 0.4; impurity 1, about 0.6; impurity 4, about 1.7; impurity 2, about 2.4.<\/p>\n
SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (4):<\/p>\n
the resolution between the peaks due to impurity 3 and phenindione is at least 6.0; the resolution between the peaks due to phenindione and impurity 4 is at least 8.0.<\/p>\n
LIMITS<\/h4>\n
In the chromatogram obtained with solution (1):<\/p>\n
the area of any peak corresponding to impurity 1 is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (1.5%);<\/p>\n
the area of any other secondary peak is not greater than half the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);<\/p>\n
the total impurity content is not greater than 2.0%.<\/p>\n
Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (5) (0.1%).<\/p>\n
ASSAY<\/h2>\n
Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions prepared immediately before use.<\/p>\n
Solution A 2% v\/v glacial acetic acid in acetonitrile.<\/p>\n
(1) Mix with the aid of ultrasound a quantity of powdered tablets containing 25 mg of Phenindione in 20 mL of 0.01M
\nsodium hydroxide and 50 mL of solution A. Dilute to 100 mL with solution A, centrifuge and use the supernatant liquid.<\/p>\n
(2) 0.025% w\/v of phenindione BPCRS in a mixture of 20 volumes of 0.01M sodium hydroxide and 80 volumes of solution A.<\/p>\n
(3) 0.025% w\/v phenindione BPCRS and phenylacetic acid (impurity 3) in a mixture of 20 volumes of 0.01M sodium hydroxide and 80 volumes of solution A.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
(a) A stainless steel column (25 cm \u00d7 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (5 \u00b5m) (Symmetry C18 is suitable).<\/p>\n
(b) Use isocratic elution and the mobile phase described below.<\/p>\n
(c) Use a flow rate of 1.0 mL per minute.<\/p>\n
(d) Use an ambient column temperature.<\/p>\n
(e) Use an autosampler temperature of 4\u00b0.<\/p>\n
(f) Use a detection wavelength of 250 nm.<\/p>\n
(g) Inject 10 \u00b5L of each solution.<\/p>\n
MOBILE PHASE<\/h3>\n
40 volumes acetonitrile and 60 volumes of 0.68 % w\/v potassium dihydrogen phosphate previously adjusted to pH 3.5 with orthophosphoric acid.<\/p>\n
SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity 3 and phenindione is at least 6.0.<\/p>\n
DETERMINATION OF CONTENT<\/h3>\n
Calculate the content of C_{15<\/sub>H_{10<\/sub>O_{2<\/sub> in the tablets using the declared content of C_{15<\/sub>H_{10<\/sub>O_{2<\/sub> in phenindione BPCRS.<\/p>\n}}}}}}
IMPURITIES<\/h2>\n
The impurities limited by the requirements of this monograph include those listed under Phenindione.<\/p>\n","protected":false},"excerpt":{"rendered":"
Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Oral anticoagulant (indanedione). DEFINITION Phenindione Tablets contain Phenindione. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of phenindione, C15H10O2 95.0 to 105.0% of the stated amount. IDENTIFICATION Shake a quantity of the powdered tablets containing 0.2 g of…<\/p>\n","protected":false},"author":5,"featured_media":20110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-20109","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/20109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=20109"}],"version-history":[{"count":4,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/20109\/revisions"}],"predecessor-version":[{"id":20179,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/20109\/revisions\/20179"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/20110"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=20109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=20109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=20109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Time(Minutes)<\/strong><\/td>\n	Mobile phase A (%v\/v)<\/strong><\/td>\n	Mobile phase B (%v\/v)<\/strong><\/td>\n	Comment<\/strong><\/td>\n<\/tr>\n
0-0.5<\/td>\n	80<\/td>\n	20<\/td>\n	isocratic<\/td>\n<\/tr>\n
0.5-10<\/td>\n	80\u219250<\/td>\n	20\u219250<\/td>\n	linear gradient<\/td>\n<\/tr>\n
10-13<\/td>\n	50<\/td>\n	50<\/td>\n	isocratic<\/td>\n<\/tr>\n
13-21<\/td>\n	50\u219230<\/td>\n	50\u219270<\/td>\n	linear gradient<\/td>\n<\/tr>\n
21-22<\/td>\n	30\u219280<\/td>\n	70\u219220<\/td>\n	linear gradient<\/td>\n<\/tr>\n
22-25<\/td>\n	80<\/td>\n	20<\/td>\n	re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to phenindione (retention time, about 7 minutes) are: impurity 5, about 0.2; impurity 3, about 0.4; impurity 1, about 0.6; impurity 4, about 1.7; impurity 2, about 2.4.<\/p>\n SYSTEM SUITABILITY<\/h4>\n The test is not valid unless, in the chromatogram obtained with solution (4):<\/p>\n the resolution between the peaks due to impurity 3 and phenindione is at least 6.0; the resolution between the peaks due to phenindione and impurity 4 is at least 8.0.<\/p>\n LIMITS<\/h4>\n In the chromatogram obtained with solution (1):<\/p>\n the area of any peak corresponding to impurity 1 is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (1.5%);<\/p>\n the area of any other secondary peak is not greater than half the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);<\/p>\n the total impurity content is not greater than 2.0%.<\/p>\n Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (5) (0.1%).<\/p>\n ASSAY<\/h2>\n Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions prepared immediately before use.<\/p>\n Solution A 2% v\/v glacial acetic acid in acetonitrile.<\/p>\n (1) Mix with the aid of ultrasound a quantity of powdered tablets containing 25 mg of Phenindione in 20 mL of 0.01M \nsodium hydroxide and 50 mL of solution A. Dilute to 100 mL with solution A, centrifuge and use the supernatant liquid.<\/p>\n (2) 0.025% w\/v of phenindione BPCRS in a mixture of 20 volumes of 0.01M sodium hydroxide and 80 volumes of solution A.<\/p>\n (3) 0.025% w\/v phenindione BPCRS and phenylacetic acid (impurity 3) in a mixture of 20 volumes of 0.01M sodium hydroxide and 80 volumes of solution A.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/h3>\n (a) A stainless steel column (25 cm \u00d7 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (5 \u00b5m) (Symmetry C18 is suitable).<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 1.0 mL per minute.<\/p>\n (d) Use an ambient column temperature.<\/p>\n (e) Use an autosampler temperature of 4\u00b0.<\/p>\n (f) Use a detection wavelength of 250 nm.<\/p>\n (g) Inject 10 \u00b5L of each solution.<\/p>\n MOBILE PHASE<\/h3>\n 40 volumes acetonitrile and 60 volumes of 0.68 % w\/v potassium dihydrogen phosphate previously adjusted to pH 3.5 with orthophosphoric acid.<\/p>\n SYSTEM SUITABILITY<\/h3>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity 3 and phenindione is at least 6.0.<\/p>\n DETERMINATION OF CONTENT<\/h3>\n Calculate the content of C_{15<\/sub>H_{10<\/sub>O_{2<\/sub> in the tablets using the declared content of C_{15<\/sub>H_{10<\/sub>O_{2<\/sub> in phenindione BPCRS.<\/p>\n}}}}}} IMPURITIES<\/h2>\n The impurities limited by the requirements of this monograph include those listed under Phenindione.<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Oral anticoagulant (indanedione). DEFINITION Phenindione Tablets contain Phenindione. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of phenindione, C15H10O2 95.0 to 105.0% of the stated amount. IDENTIFICATION Shake a quantity of the powdered tablets containing 0.2 g of…<\/p>\n","protected":false},"author":5,"featured_media":20110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-20109","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/20109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=20109"}],"version-history":[{"count":4,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/20109\/revisions"}],"predecessor-version":[{"id":20179,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/20109\/revisions\/20179"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/20110"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=20109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=20109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=20109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

TESTS<\/h2>\n

Dissolution<\/h3>\nComply with the requirements for Monographs of the British Pharmacopoeia in the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n

TEST CONDITIONS<\/h4>\n(a)\u00a0 Use Apparatus 1, rotating the basket at 100 revolutions per minute.<\/p>\n(2) Use 900 mL of a solution containing 0.68% w\/v of potassium dihydrogen phosphate and 0.18% w\/v of sodium hydroxide, pH adjusted to 8.0, at a temperature of 37\u00b0, as the medium.<\/p>\n

DETERMINATION OF CONTENT<\/h4>\nCalculate the total content of Phenindione, C15<\/sub>H10<\/sub>O2<\/sub>, in the medium from the absorbances obtained and using the declared content of C15<\/sub>H10<\/sub>O2<\/sub> in phenindione BPCRS.<\/p>\n

SYSTEM SUITABILITY<\/h4>\nThe test is not valid unless, in the chromatogram obtained with solution (4):<\/p>\nthe resolution between the peaks due to impurity 3 and phenindione is at least 6.0; the resolution between the peaks due to phenindione and impurity 4 is at least 8.0.<\/p>\n

MOBILE PHASE<\/h3>\n40 volumes acetonitrile and 60 volumes of 0.68 % w\/v potassium dihydrogen phosphate previously adjusted to pH 3.5 with orthophosphoric acid.<\/p>\n

SYSTEM SUITABILITY<\/h3>\nThe test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity 3 and phenindione is at least 6.0.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\nCalculate the content of C15<\/sub>H10<\/sub>O2<\/sub> in the tablets using the declared content of C15<\/sub>H10<\/sub>O2<\/sub> in phenindione BPCRS.<\/p>\n

Dissolution<\/h3>\n
Comply with the requirements for Monographs of the British Pharmacopoeia in the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n

DETERMINATION OF CONTENT<\/h4>\n
Calculate the total content of Phenindione, C_{15<\/sub>H_{10<\/sub>O_{2<\/sub>, in the medium from the absorbances obtained and using the declared content of C_{15<\/sub>H_{10<\/sub>O_{2<\/sub> in phenindione BPCRS.<\/p>\n}}}}}}

SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (4):<\/p>\n
the resolution between the peaks due to impurity 3 and phenindione is at least 6.0; the resolution between the peaks due to phenindione and impurity 4 is at least 8.0.<\/p>\n

MOBILE PHASE<\/h3>\n
40 volumes acetonitrile and 60 volumes of 0.68 % w\/v potassium dihydrogen phosphate previously adjusted to pH 3.5 with orthophosphoric acid.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity 3 and phenindione is at least 6.0.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\n
Calculate the content of C_{15<\/sub>H_{10<\/sub>O_{2<\/sub> in the tablets using the declared content of C_{15<\/sub>H_{10<\/sub>O_{2<\/sub> in phenindione BPCRS.<\/p>\n}}}}}}